Biopharma
- Value of transaction is expected to close in fourth quarter of 2024
- Deal includes UCB’s neurology and allergy portfolios
© 2026 SAUDI RESEARCH & PUBLISHING COMPANY, All Rights Reserved And subject to Terms of Use Agreement.








